Altana Omnaris Pediatric Program Had No Room For Error
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Poorly executed pediatric trials impeded Altana’s attempt to gain approval of Omnaris (ciclesonide) nasal spray in children under 12 years old, FDA review documents indicate.